Research / SOFI / Fundamental state Inspectable configuration
State dimensions Filing 0001818874-23-000018 Bank
Sequential deposit growth RAW Current state valid · history insufficient
Evidence method Sequential · gp.financial.deposits
45.92% · CORE · NOT_ENOUGH_HISTORY
Interest-expense growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.financial.interest_expense
84.16% · CORE · NOT_ENOUGH_HISTORY
Cash and equivalents 100th Own-history percentile · N=9
Evidence method Level · gp.fundamentals.cash
$1.4B · CORE · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 17 states Self-history eligible
Jun 30, 2022 0/3 normalized Level 3 Sep 30, 2022 1/3 normalized Level 3 Dec 31, 2022 1/3 normalized Level 3 Mar 31, 2023 1/3 normalized Level 3 Jun 30, 2023 1/3 normalized Level 3 Sep 30, 2023 1/3 normalized Level 3 Dec 31, 2023 1/3 normalized Level 3 Mar 31, 2024 1/3 normalized Level 3 Jun 30, 2024 2/3 normalized Level 3 Sep 30, 2024 2/3 normalized Level 3 Dec 31, 2024 2/3 normalized Level 3 Mar 31, 2025 2/4 normalized Level 3 Jun 30, 2025 2/4 normalized Level 3 Sep 30, 2025 2/4 normalized Level 3 Dec 31, 2025 2/4 normalized Level 3 Mar 31, 2026 2/4 normalized Level 3 Jun 30, 2026 3/4 normalized Level 4 Period transition
What moved in the state? Deposit Growth Decreased
Previous 85.51%
Current 45.92%
Delta -39.59% Funding Cost Growth Decreased
Previous 89.34%
Current 84.16%
Delta -5.18% Liquidity Increased
Previous $935.2M
Current $1.4B
Delta $486.7M Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.